Rapidly progressive primary undifferentiated ovarian carcinoma: presentation of a rare case

Ovarian cancer is the second most common gynecologic malignancy and is one of the leading causes of death among women. The disease course and the accurate diagnosis are correlated with the early detection of the lesion. About 5% of ovarian cancers are poorly differentiated and difficult to be classified, and are referred to as undifferentiated carcinomas. They are usually large, solid with haemorrhage and necrosis, bilateral, and very difficult to be histologically classified. Generally, cases with undifferentiated components are very rare. The authors present a case of a young female patient with a rapidly progressive undifferentiated ovarian carcinoma and a final unfortunate clinical result.

Ovarian cancer; Undifferentiated carcinoma; Necrosis.

[1] Siegel R., Naishadham D., Jemal A.: “Cancer statistics, 2012”. CA Cancer J. Clin., 2012, 62, 10.

[2] Aletti G.D., Gallenberg M.M., Cliby W.A., Jatoi A., Hartmann L.C.: “Current management strategies for ovarian cancer”. Mayo Clin. Proc., 2007, 82, 751.

[3] Cannistra S.A.: “Cancer of the ovary”. N. Engl. J. Med., 2004, 351, 2519.

[4] Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al.: “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2003, 21, 3194.

[5] Vaughan S., Coward J.I., Bast R.C. Jr., Berchuck A., Berek J.S., Brenton J.D., et al.: “Rethinking ovarian cancer: recommendations for improving outcomes”. Nat. Rev. Cancer, 2011, 11, 719.

[6] Cormio G., Rossi C., Cazzolla A., Resta L., Loverro G., Greco P., Selvaggi L.: “Distant metastases in ovarian carcinoma”. Int. J. Gynecol. Cancer, 2003, 13, 125.

[7] Christofori G.: “New signals from the invasive front”. Nature, 2006, 441, 444.

[8] Kurtz A.B., Tsimikas J.V., Tempany C.M., Hamper U.M., Arger P.H., Bree R.L., et al.: “Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR Imaging correlated with surgery and histopathologic analysis-Report of the Radiology Diagnostic Oncology Group”. Radiology, 1999, 212, 19.

[9] Kawamoto S., Urban B.A., Fishman E.K.: “CT of epithelial ovarian tumours”. Radiographics, 1999, 19, S85.

[10] Jeong Y.Y., Outwater E.K., Kang H.K.: “Imaging evaluation of ovarian masses”. Radiographics, 2000, 20, 1445.

[11] Hricak H., Chen M., Coakley F.V., Kinkel K., Yu K.K., Sica G., et al.: “Complex adnexal masses: detection and characterization with MR imaging-Multivariate analysis”. Radiology, 2000, 214, 39.

[12] Khoo S.K., Battistutta D., Hurst T., Sanderson B., Ward B.G., Free K.: “The prognostic value of clinical, pathologic, and biologic parameters in ovarian cancer”. Cancer, 1993, 72, 531.

[13] Brown D.L., Zou K.H., Tempany C.M., Frates M.C., Silverman S.G., McNeil B.J., Kurtz A.B.: “Primary versus secondary ovarian malignancy: imaging findings of adnexal masses in the Radiology Diagnostic Oncology Group Study”. Radiology, 2001, 219, 213.

[14] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D.: “Global cancer statistics”. CA Cancer J. Clin., 2011, 61, 69.

[15] Siegel R., Ward E., Brawley O., Jemal A.: “Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths”. CA Cancer J. Clin., 2011, 61, 212.

[16] Ferlay J., Bray F., Pisani P., Parkin D.M.: “GLOBOCAN 2002. Cancer inci dence, mortality and prevalence worldwide”. IARC Cancer- Base No. 5, version 2.0. Lyon: IARC Press, 2004.

[17] Silva E.G, Tornos C., Bailey M.A, Morris M.: “Undiffrentiated carcinoma of the ovary”. Arch. Pathol. Lab. Med., 1991, 115, 377.

[18] Silva E.G., Deavers M.T., Bodurka D.C., Malpica A.: “Association of low grade endometroid carcinoma: a new type of differentiated carcinoma?” Int. J. Gynecol. Pathol., 2006, 25, 52.